Press Releases Year All202120202019 02/23/21 Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity 01/11/21 Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones 01/04/21 Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference 12/22/20 Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation 12/15/20 Kiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo Nodularis 11/30/20 Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404 11/24/20 Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference 11/23/20 Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis 11/17/20 Kiniksa Announces New England Journal of Medicine Publication of Rilonacept Phase 3 Data in Recurrent Pericarditis and Late-Breaking Science Presentation at American Heart Association Scientific Sessions 2020 11/16/20 Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis 11/09/20 Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data 11/05/20 Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity 10/29/20 Kiniksa Announces Phase 2 Clinical Data from Vixarelimab in Prurigo Nodularis Presented at European Academy of Dermatology and Venereology Virtual Congress 10/26/20 Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020 10/06/20 Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis 09/24/20 Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th 09/21/20 Kiniksa Announces Upcoming Rilonacept Analyst Day 09/15/20 Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis 09/09/20 Kiniksa Pharmaceuticals to Present at the Morgan Stanley 18th Annual Global Healthcare Conference 08/31/20 Kiniksa Presents Data on the Burden of Disease in Patients with Recurrent Pericarditis at the European Society of Cardiology Congress 2020 08/04/20 Kiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Conference 07/30/20 Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity 07/21/20 Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering 07/20/20 Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering 07/16/20 Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis 06/29/20 Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY) 06/17/20 Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19 06/10/20 Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts 06/08/20 Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial 06/04/20 Kiniksa Pharmaceuticals to Present at 41st Annual Goldman Sachs Global Healthcare Conference 05/29/20 Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at the European E-Congress of Rheumatology 2020 05/18/20 Kiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 05/13/20 Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering 05/13/20 Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering 05/11/20 Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus 04/28/20 Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity 04/22/20 Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint 03/31/20 Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation 03/30/20 Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session 02/26/20 Kiniksa Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity 01/13/20 Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts 12/11/19 Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma 12/10/19 Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference 11/20/19 Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference 11/20/19 Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis 11/16/19 Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019 11/12/19 Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting 10/28/19 Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity 09/19/19 Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research 08/19/19 Kiniksa to Present Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019 08/12/19 Kiniksa Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity 08/12/19 Kiniksa Announces Interim Data from KPL-716 Repeated-Single-Dose Phase 1b Clinical Trial 08/06/19 Kiniksa Pharmaceuticals to Present at the 2019 Wedbush PacGrow Healthcare Conference 08/05/19 Kiniksa Pharmaceuticals Announces Collaboration with the Myocarditis Foundation for the Pericarditis Community 06/12/19 Kiniksa Presents Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at the Annual European Congress of Rheumatology 05/30/19 Kiniksa to Present Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at EULAR 2019 05/29/19 Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences 05/16/19 Kiniksa to Present Data on the Burden of Disease in Patients with Recurrent Pericarditis at the International Society for Pharmacoeconomics and Outcomes Research 05/13/19 Kiniksa Presents Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology 05/02/19 Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity 04/17/19 Kiniksa to Present Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology 04/08/19 Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs 03/18/19 Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiology’s 68th Annual Scientific Session 03/07/19 Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity 02/28/19 Kiniksa Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference 02/26/19 Kiniksa Pharmaceuticals to Present at the Barclays Global Healthcare Conference 01/31/19 Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering 01/28/19 Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering and Concurrent Private Placement 01/03/19 Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab 12/17/18 Kiniksa Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference 12/11/18 Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data and Initiates Pivotal Phase 3 Clinical Trial 12/06/18 Kiniksa Provides Update on U.S. FDA Review of Investigational New Drug Application for Mavrilimumab in Giant Cell Arteritis 11/01/18 Kiniksa Reports Third Quarter 2018 Financial Results and Pipeline Progress 09/15/18 Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology 08/29/18 Kiniksa to Present Late-Breaking KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology 08/28/18 Kiniksa Pharmaceuticals to Present at the 2018 Wells Fargo Healthcare Conference 08/06/18 Kiniksa Reports Second Quarter 2018 Financial Results and Pipeline Progress 08/02/18 Kiniksa Pharmaceuticals to Present at the 2018 Wedbush PacGrow Healthcare Conference 06/25/18 Kiniksa Pharmaceuticals, Ltd. Announces Exercise of the Underwriters’ Option to Purchase Additional Shares 06/14/18 Kiniksa Pharmaceuticals to Present at the JMP Securities 2018 Life Sciences Conference 05/29/18 Kiniksa Pharmaceuticals, Ltd. Announces Closing of Initial Public Offering 05/23/18 Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Initial Public Offering 12/21/17 Kiniksa Pharmaceuticals to Present at 36th Annual J.P. Morgan Healthcare Conference 12/20/16 Sanj K. Patel to Introduce Kiniksa Pharmaceuticals at 35th Annual J.P. Morgan Healthcare Conference
